An open-label pilot study suggests that intravenous brexanolone may rapidly reduce psychotic, manic, and depressive symptoms in patients with postpartum psychosis, highlighting a potential new treatment option.
Blood levels of neuroactive steroids during the third trimester of pregnancy may predict increased risk of postpartum depression, offering possibility for early intervention.
A new study from Hantsoo and colleagues asks whether SRI treatment affects the levels of neuroactive steroids modulating GABA-A receptors.
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
In this phase II study, sepranolone 10 mg administered subcutaneously during the late luteal phase reduced PMDD symptoms more than placebo.
Neuroactive steroids, derivatives of allopregnanolone, may be effective for the treatment of premenstrual dysphoric disorder.
This article focuses on how GABA-ergic neurotransmitter systems may modulate the interaction between reproductive steroid and sex steroid systems, and sheds light on the role allopregnanolone may play in medicating vulnerability to depression.Â
Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can [...]
Sepranolone is a neuroseroid now in Phase II clinical trials for the treatment of premenstrual dysphoric disorder (PMDD). Â
